523 related articles for article (PubMed ID: 33208326)
21. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
22. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
23. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
24. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():51-60. PubMed ID: 28683982
[TBL] [Abstract][Full Text] [Related]
25. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
Mafirakureva N; Stone J; Fraser H; Nzomukunda Y; Maina A; Thiong'o AW; Kizito KW; Mucara EWK; González Diaz CI; Musyoki H; Mundia B; Cherutich P; Nyakowa M; Lizcano J; Chhun N; Kurth A; Akiyama MJ; Waruiru W; Bhattacharjee P; Cleland C; Donchuk D; Luhmann N; Loarec A; Maman D; Walker J; Vickerman P
Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
[TBL] [Abstract][Full Text] [Related]
26. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
28. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
Bota S; Razpotnik M; Hucke F; Urak C; Flatscher K; Peck-Radosavljevic M
Wien Klin Wochenschr; 2021 Jul; 133(13-14):641-646. PubMed ID: 34032930
[TBL] [Abstract][Full Text] [Related]
29. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
30. The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC).
Lazarus JV; Øvrehus A; Demant J; Krohn-Dehli L; Weis N
BMJ Open; 2020 Nov; 10(11):e039724. PubMed ID: 33168560
[TBL] [Abstract][Full Text] [Related]
31. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
[TBL] [Abstract][Full Text] [Related]
32. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.
Tai CM; Yu ML
Kaohsiung J Med Sci; 2024 Feb; 40(2):112-118. PubMed ID: 38010851
[TBL] [Abstract][Full Text] [Related]
34. Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
O'Keefe D; Gunn J; Ryan K; Djordjevic F; Kerr P; Gold J; Elsum I; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana AE
BMJ Open; 2022 Jan; 12(1):e057618. PubMed ID: 34983773
[TBL] [Abstract][Full Text] [Related]
35. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
38. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
[TBL] [Abstract][Full Text] [Related]
39. Belgian experience with direct acting antivirals in people who inject drugs.
Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixko C; Decaestecker J; De Galocsy C; Janssens F; Cool M; Van Overbeke L; Van Steenkiste C; D'heygere F; Cools W; Nevens F; Robaeys G
Drug Alcohol Depend; 2017 Aug; 177():214-220. PubMed ID: 28618285
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
